These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 17239324

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
    Jin Y, Sun W, Gu D, Yang J, Xu Z, Chen J.
    Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
    [Abstract] [Full Text] [Related]

  • 4. Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis.
    Grunberg SM, Koeller JM.
    Expert Opin Pharmacother; 2003 Dec; 4(12):2297-303. PubMed ID: 14640928
    [Abstract] [Full Text] [Related]

  • 5. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
    Navari RM.
    Future Oncol; 2006 Oct; 2(5):591-602. PubMed ID: 17026451
    [Abstract] [Full Text] [Related]

  • 6. Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery.
    Balfour JA, Goa KL.
    Drugs; 1997 Aug; 54(2):273-98. PubMed ID: 9257083
    [Abstract] [Full Text] [Related]

  • 7. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S.
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [Abstract] [Full Text] [Related]

  • 8. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
    Billio A, Morello E, Clarke MJ.
    Cochrane Database Syst Rev; 2010 Jan 20; (1):CD006272. PubMed ID: 20091591
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S, 99-04 Palonosetron Study Group.
    Cancer; 2003 Dec 01; 98(11):2473-82. PubMed ID: 14635083
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting.
    Lorusso V, Karthaus M, Aapro M.
    Future Oncol; 2015 Dec 01; 11(4):565-77. PubMed ID: 25360998
    [Abstract] [Full Text] [Related]

  • 14. 5HT3-receptor antagonists as antiemetics in cancer.
    Drug Ther Bull; 2005 Aug 01; 43(8):57-62. PubMed ID: 16111085
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting.
    Mori-Vogt S, Blazer M.
    Expert Rev Anticancer Ther; 2013 Aug 01; 13(8):919-36. PubMed ID: 23984894
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.